Esther Drill
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Esther Drill has a total of 380 co-authors. Here are the top co-authors by number of shared publications:
- Ghassan K. Abou-Alfa
Memorial Sloan Kettering Cancer Center, New York, New York, USA
50 shared publications - James J. Harding
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY
50 shared publications - William Robert Jarnagin
Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
50 shared publications - Nikolaus Schultz
Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
49 shared publications - Eileen Mary O'Reilly
Weill Cornell Medicine
27 shared publications - Alice C. Wei
Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
26 shared publications
Latest Publications
- 8 September 2026
- Published by American Society of Hematology in Blood
Pembrolizumab-GVD in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter phase 2 trial
A phase II trial assessed the safety and efficacy of pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin (pembrolizumab-GVD) in transplant-eligible patients with relapsed/refractory (rel/rel) cHL, and demonstrated a complete response (CR) rate of 95% and progression-free survival (PFS) of 100% at 13.5 months (NCT03618550). We present an updated analysis of this trial at 5 years. Eligible patients received pembrolizumab 200mg intravenous (IV) (day 1), gemcitabine 1,000mg/m2 IV (days 1 and 8), vinorelbine 20mg/m2 IV (days 1 and 8), and liposomal doxorubicin 15mg/m2 IV (days 1 and 8) in 21-day cycles, followed by high-dose chemotherapy and autologous stem cell rescue (HDT/ASCR). Of 39 enrolled patients, 41% had primary refractory disease and 38% relapsed within 1 year of first-line treatment. In 38 response-evaluable patients, the CR and overall response rates after up to 4 cycles of pembrolizumab-GVD were 95% and 100%, respectively, with 35 patients (92%) attaining CR after only 2 cycles of therapy. Thirty-six (95%) patients underwent HDT/ASCR. After a median follow-up of 57 months, 1 patient experienced disease recurrence after per-protocol therapy, and 2 patients died from non-relapse or treatment-related causes. Estimated 5-year PFS and OS were 91% and 94%, respectively. No new safety signals were identified with extended follow-up.
- 8 September 2026
- Published by American Society of Hematology in Blood
Pembrolizumab-GVD in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter phase 2 trial
A phase II trial assessed the safety and efficacy of pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin (pembrolizumab-GVD) in transplant-eligible patients with relapsed/refractory (rel/rel) cHL, and demonstrated a complete response (CR) rate of 95% and progression-free survival (PFS) of 100% at 13.5 months (NCT03618550). We present an updated analysis of this trial at 5 years. Eligible patients received pembrolizumab 200mg intravenous (IV) (day 1), gemcitabine 1,000mg/m2 IV (days 1 and 8), vinorelbine 20mg/m2 IV (days 1 and 8), and liposomal doxorubicin 15mg/m2 IV (days 1 and 8) in 21-day cycles, followed by high-dose chemotherapy and autologous stem cell rescue (HDT/ASCR). Of 39 enrolled patients, 41% had primary refractory disease and 38% relapsed within 1 year of first-line treatment. In 38 response-evaluable patients, the CR and overall response rates after up to 4 cycles of pembrolizumab-GVD were 95% and 100%, respectively, with 35 patients (92%) attaining CR after only 2 cycles of therapy. Thirty-six (95%) patients underwent HDT/ASCR. After a median follow-up of 57 months, 1 patient experienced disease recurrence after per-protocol therapy, and 2 patients died from non-relapse or treatment-related causes. Estimated 5-year PFS and OS were 91% and 94%, respectively. No new safety signals were identified with extended follow-up.
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (8) , e2501261
Evaluating the Prognostic Impact of IDH Mutations in Intrahepatic Cholangiocarcinoma
PURPOSE: Isocitrate dehydrogenase 1 and 2 ( IDH1 and IDH2 ) mutations are common in intrahepatic cholangiocarcinoma (ICC), but their prognostic value is unclear. Using a large data set, we assessed their impact in resected and nonresected ICC. METHODS: Adults from two medical centers (MSKCC and Erasmus) with ICC treated with curative-intent resection (resected) or managed nonoperatively (unresectable) who underwent next-generation sequencing were analyzed retrospectively. Kaplan-Meier and Cox regressions assessed the impact of IDH status on outcomes. RESULTS: Of the 795 patients analyzed, 25% had IDH1/2 mutations ( IDH mut) and 43% underwent resection. Median overall survival (OS) of the cohort was 32 months in IDH mut and 28 months for IDH wt ( P = .2). High-risk genetic alterations ( TP53 mut, KRAS mut, and CDKN2A del) were more frequent in IDH wild-type ( IDH wt; odds ratio, 2.26; q < 0.001). OS was 19 months in patients with high-risk alterations versus 40 months in patients without ( P < .001). In resected patients, recurrence-free survival (RFS) in IDH mut was 20 months versus 14 months for IDH wt ( P = .018), and OS was 69 months versus 50 months, respectively ( P = .2). However, after controlling for high-risk alterations, the potential benefit of IDH mut was no longer apparent (RFS: hazard ratio [HR], 0.78; P = .095; OS: HR, 0.88; P = .4). In unresectable IDH mut patients, progression-free survival was 9.4 months versus 9.1 months for IDH wt ( P = .7), and OS was 22 months versus 18 months, respectively ( P = .13). There remained no differences after controlling for high-risk alterations. IDH status was not a significant survival predictor in multivariable models. CONCLUSION: In this cohort of patients with ICC, IDH mut was not an independent predictor of survival, after controlling for high-risk alterations and clinical variables. IDH mutational status alone should, therefore, not be used to guide prognosis.
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (8) , e2501261
Evaluating the Prognostic Impact of IDH Mutations in Intrahepatic Cholangiocarcinoma
PURPOSE: Isocitrate dehydrogenase 1 and 2 ( IDH1 and IDH2 ) mutations are common in intrahepatic cholangiocarcinoma (ICC), but their prognostic value is unclear. Using a large data set, we assessed their impact in resected and nonresected ICC. METHODS: Adults from two medical centers (MSKCC and Erasmus) with ICC treated with curative-intent resection (resected) or managed nonoperatively (unresectable) who underwent next-generation sequencing were analyzed retrospectively. Kaplan-Meier and Cox regressions assessed the impact of IDH status on outcomes. RESULTS: Of the 795 patients analyzed, 25% had IDH1/2 mutations ( IDH mut) and 43% underwent resection. Median overall survival (OS) of the cohort was 32 months in IDH mut and 28 months for IDH wt ( P = .2). High-risk genetic alterations ( TP53 mut, KRAS mut, and CDKN2A del) were more frequent in IDH wild-type ( IDH wt; odds ratio, 2.26; q < 0.001). OS was 19 months in patients with high-risk alterations versus 40 months in patients without ( P < .001). In resected patients, recurrence-free survival (RFS) in IDH mut was 20 months versus 14 months for IDH wt ( P = .018), and OS was 69 months versus 50 months, respectively ( P = .2). However, after controlling for high-risk alterations, the potential benefit of IDH mut was no longer apparent (RFS: hazard ratio [HR], 0.78; P = .095; OS: HR, 0.88; P = .4). In unresectable IDH mut patients, progression-free survival was 9.4 months versus 9.1 months for IDH wt ( P = .7), and OS was 22 months versus 18 months, respectively ( P = .13). There remained no differences after controlling for high-risk alterations. IDH status was not a significant survival predictor in multivariable models. CONCLUSION: In this cohort of patients with ICC, IDH mut was not an independent predictor of survival, after controlling for high-risk alterations and clinical variables. IDH mutational status alone should, therefore, not be used to guide prognosis.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Table S1. Sample list (cBioPortal identifiers, ‘DMP_SAMPLE_ID’). Only the primary tumor (if available) or the earliest collected metastasis are included (n=233)
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Table S1. Sample list (cBioPortal identifiers, ‘DMP_SAMPLE_ID’). Only the primary tumor (if available) or the earliest collected metastasis are included (n=233)
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Table S2. Oncogenic/Likely-oncogenic structural variants in GBC
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention
Table S2. Oncogenic/Likely-oncogenic structural variants in GBC
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Supplementary Tables and Figures
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Supplementary Tables and Figures